CC - The Chemours Company

NYSE - Nasdaq Real-time price. Currency in USD
13.32
+0.22 (+1.64%)
As of 9:45AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close13.11
Open13.26
Bid13.19 x 800
Ask13.36 x 3000
Day's range13.03 - 13.38
52-week range7.02 - 25.35
Volume63,082
Avg. volume3,274,050
Market cap2.188B
Beta (5Y monthly)2.38
PE ratio (TTM)N/A
EPS (TTM)-0.28
Earnings date30 Jul 2020 - 03 Aug 2020
Forward dividend & yield1.00 (7.35%)
Ex-dividend date14 May 2020
1y target est12.73
  • The Chemours Company Just Beat EPS By 39%: Here's What Analysts Think Will Happen Next
    Simply Wall St.

    The Chemours Company Just Beat EPS By 39%: Here's What Analysts Think Will Happen Next

    It's been a good week for The Chemours Company (NYSE:CC) shareholders, because the company has just released its...

  • The Chemours Company (CC) Q1 2020 Earnings Call Transcript
    Motley Fool

    The Chemours Company (CC) Q1 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to the Chemours Company First quarter Earnings Call. Before we start, I'd like to remind you that comments made on this call as well as the supplemental information provided in our presentation and on our website contain forward-looking statements that involve risks and uncertainties, including the impact of COVID-19 on our business and operations and the other risks and uncertainties described in the documents Chemours has filed with the SEC.

  • Why Chemours Stock Jumped 13% Today
    Motley Fool

    Why Chemours Stock Jumped 13% Today

    Shares of specialty chemical company Chemours (NYSE: CC) jumped nearly 14% as trading opened for the day. Although the company's titanium coatings business did well (sales were up 10% in the segment), its other two divisions (fluoroproducts and chemical solutions) saw year-over-year sales declines.

  • Chemours (CC) Earnings Beat, Revenues Miss Estimates in Q1
    Zacks

    Chemours (CC) Earnings Beat, Revenues Miss Estimates in Q1

    Decline volumes in the Fluoroproducts unit and lower global average prices across all segments hurt Chemours' (CC) Q1 sales.

  • Chemours (CC) Tops Q1 Earnings Estimates
    Zacks

    Chemours (CC) Tops Q1 Earnings Estimates

    Chemours (CC) delivered earnings and revenue surprises of 39.22% and -2.77%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Why Shares of Chemours Are Soaring Today
    Motley Fool

    Why Shares of Chemours Are Soaring Today

    The company's former parent expects to settle a dispute over retained environmental liabilities.

  • Earnings Preview: Chemours (CC) Q1 Earnings Expected to Decline
    Zacks

    Earnings Preview: Chemours (CC) Q1 Earnings Expected to Decline

    Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Easy Come, Easy Go: How Chemours (NYSE:CC) Shareholders Got Unlucky And Saw 76% Of Their Cash Evaporate
    Simply Wall St.

    Easy Come, Easy Go: How Chemours (NYSE:CC) Shareholders Got Unlucky And Saw 76% Of Their Cash Evaporate

    The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...

  • Chemours Provides Update in Response to Coronavirus Outbreak
    Zacks

    Chemours Provides Update in Response to Coronavirus Outbreak

    Chemours (CC) is likely to use the $300-million proceeds from borrowings in the future for working capital needs or other general corporate purposes.

  • Are Options Traders Betting on a Big Move in Chemours (CC) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in Chemours (CC) Stock?

    Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.

  • Here's Why You Should Hold Onto Chemours (CC) Stock Now
    Zacks

    Here's Why You Should Hold Onto Chemours (CC) Stock Now

    Chemours (CC) should gain from its actions to drive Opteon adoption and boost productivity across its business segments in 2020.

  • Chemours (CC) Down 34.3% Since Last Earnings Report: Can It Rebound?
    Zacks

    Chemours (CC) Down 34.3% Since Last Earnings Report: Can It Rebound?

    Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Chemours (CC) Inaugurates State-of-the-art Innovation Center
    Zacks

    Chemours (CC) Inaugurates State-of-the-art Innovation Center

    Chemours' (CC) new facility is one of Delaware's biggest R&D centers and one of the largest R&D facilities in the chemical industry.

  • Trade Alert: The Independent Chairman of the Board Of The Chemours Company (NYSE:CC), Richard Brown, Has Just Spent US$105k Buying Shares
    Simply Wall St.

    Trade Alert: The Independent Chairman of the Board Of The Chemours Company (NYSE:CC), Richard Brown, Has Just Spent US$105k Buying Shares

    Investors who take an interest in The Chemours Company (NYSE:CC) should definitely note that the Independent Chairman...

  • We Wouldn't Be Too Quick To Buy The Chemours Company (NYSE:CC) Before It Goes Ex-Dividend
    Simply Wall St.

    We Wouldn't Be Too Quick To Buy The Chemours Company (NYSE:CC) Before It Goes Ex-Dividend

    It looks like The Chemours Company (NYSE:CC) is about to go ex-dividend in the next 4 days. Investors can purchase...

  • Chemours (CC) Earnings Beat, Revenues Miss Estimates in Q4
    Zacks

    Chemours (CC) Earnings Beat, Revenues Miss Estimates in Q4

    Lower volumes and prices in Titanium Technologies and Fluoroproducts units hurt Chemours' (CC) Q4 sales.

  • Implied Volatility Surging for Chemours (CC) Stock Options
    Zacks

    Implied Volatility Surging for Chemours (CC) Stock Options

    Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.

  • Chemours (CC) to Post Q4 Earnings: What's in the Cards?
    Zacks

    Chemours (CC) to Post Q4 Earnings: What's in the Cards?

    Our proven model does not predict an earnings beat for Chemours (CC) this season.

  • Is The Chemours Company's (NYSE:CC) CEO Pay Fair?
    Simply Wall St.

    Is The Chemours Company's (NYSE:CC) CEO Pay Fair?

    Mark Vergnano became the CEO of The Chemours Company (NYSE:CC) in 2015. This report will, first, examine the CEO...

  • When Face Masks Are a 3M Big Seller, That’s Telling
    Bloomberg

    When Face Masks Are a 3M Big Seller, That’s Telling

    (Bloomberg Opinion) -- 3M Co.’s messy quarter does little to inspire faith in the company or the industrial economy at large.The maker of Post-it notes, Scotch tape and wound dressings announced a pair of charges – $134 million for a restructuring plan and $214 million for litigation related to PFAS chemicals – that pulled its fourth-quarter earnings per share below analysts’ estimates. 3M’s particular issues aside, the company sits on the front lines of any economic swings, and there was scant evidence in its results that the great industrial turnaround heralded by President Donald Trump’s trade truce with China has in fact arrived.Sales at 3M fell 2.6% in the fourth quarter after backing out the impact of acquisitions and currency swings, leaving the company with its biggest annual decline on that basis since 2009. With U.S. tariffs still in place on some $360 billion of Chinese goods, political uncertainty tied to the American presidential election and few specifics about alleged purchasing commitments from China — not to mention the potential economic impact of the widening coronavirus crisis — a recovery is apt to be more muted.(1) 3M’s concerns run deeper than just a weak macroeconomic backdrop, though. PFAS — which stands for per- and polyfluoroalkyl substances — are  known as the “forever chemicals” because they don’t break down in the environment and accumulate in the body. They have been linked to health problems including cancer and immune system dysfunction, spurring a series of lawsuits against manufacturers including 3M and DuPont de Nemours Inc.’s Chemours Co. spinoff. The charge 3M announced Tuesday reflects updated expectations for customer-related litigation and environmental matters for sites where it historically manufactured the chemical. 3M also disclosed on Tuesday that it had received a grand jury subpoena related to non-compliant discharges from an Alabama facility, and said it had discovered similar issues at an Illinois plant as part of a fourth-quarter review.The charges are a reminder of how much investors still don’t know about 3M’s financial exposure to lawsuits and potential environmental regulation. Gordon Haskett analyst John Inch has estimated 3M’s ultimate liability for PFAS – including remediation, personal injury settlements and monitoring expenses – could be about $27 billion. The company didn’t do itself any favors by waiting until the call to disclose the grand jury probe. That was General Electric Co.’s attitude in 2018 when it casually dropped a mention of a Securities and Exchange Commission investigation into some of its accounting practices an earnings call. That isn’t the company you want to keep when it comes to transparency and accountability.In that light, I treat 3M’s latest restructuring push with a dose of skepticism. The company will dismantle the international operations arm that was tasked with setting priorities for geographic regions and instead give its business groups global control over decisions affecting their strategy and resources. This is meant to be “the next step in its transformation journey” following a shakeup last year, where 3M rethought how its businesses are divided up. The idea was to group its products by customers, rather than market – i.e. sales of automotive products to retail shops would fall under the “consumer” unit rather than be lumped in with automotive revenue from manufacturers or body shops. In theory, this all makes sense and should streamline decision-making processes; 3M says it will help the company save as much as $120 million a year. But it also feels like a bit like reshuffling the deck and a convenient way to throw some corporate-speak at a plan to cut 1,500 jobs that might otherwise have felt less like a “transformation”  and more like a reaction to still stubbornly sluggish sales growth.For 2020, 3M warned organic sales may be flat at worst. That’s a weaker forecast than some analysts had been expecting, but RBC analyst Deane Dray warned even this downbeat outlook may not be pessimistic enough. It’s possible sales slump yet again, particularly given 3M’s dependence on China’s economy and the impact from the coronavirus outbreak. 3M had been modeling low-to-mid-single digit growth in China in 2020 off of depressed 2019 numbers, CEO Mike Roman said on the earnings call. While the company had already been expecting a sluggish start to the year in China largely due to still-weak automotive markets, the coronavirus is “changing things as we go,” Roman said. Offsetting the possible negative impact on China’s overall economy is the growing demand for 3M’s face masks and other respiratory-protection products.The coronavirus aside, it’s hard to give 3M the benefit of the doubt after a staggering series of guidance cuts over the course of 2018 and 2019. Even if 3M finally did get its outlook right for a change, its best-case scenario for sales growth is a meager 2% increase. Such sluggish but stabilized revenue growth is likely to describe many manufacturing companies’ performance in 2020, but unlike 3M — which declined in 2019 and fell again on Tuesday’s earnings news — many of them aren’t priced for that kind of environment.(1) Elsewhere on Tuesday, CommerceDepartmentdata showed orders for non-military capital goodsexcluding aircraft—a proxy for business investment —unexpectedly declined 0.9% in December.To contact the author of this story: Brooke Sutherland at bsutherland7@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Brooke Sutherland is a Bloomberg Opinion columnist covering deals and industrial companies. She previously wrote an M&A column for Bloomberg News.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Chemours' Opteon XP10 Refrigerants Chosen by Sharc Energy
    Zacks

    Chemours' Opteon XP10 Refrigerants Chosen by Sharc Energy

    Chemours (CC) anticipates the collaboration to help Sharc Energy engage in refrigerant solutions that are more environmentally sustainable.

  • GlobeNewswire

    Sharc Energy Selects Opteon™ XP10 (R-513A) Refrigerants for Next Generation PIRANHA™

    SHARC selected The Chemours Company FC, LLC (“Chemours”) and its Opteon™ XP10 (R-513A), because it offers a non-ozone depleting, low GWP hydrofluoro-olefin (“HFO”) based refrigerant developed with a 56% reduction to replace R-134a in positive displacement, direct expansion, medium-temperature commercial and industrial fixed speed systems, chillers, and heat pumps (HP) such as the PIRANHA™ while providing improved energy efficiency, similar capacity, and excellent design compatibility.

  • Here's How We Evaluate The Chemours Company's (NYSE:CC) Dividend
    Simply Wall St.

    Here's How We Evaluate The Chemours Company's (NYSE:CC) Dividend

    Dividend paying stocks like The Chemours Company (NYSE:CC) tend to be popular with investors, and for good reason...

  • GlobeNewswire

    3-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages The Chemours Company (CC) Investors Who Suffered Significant Losses to Contact Its Attorneys: Application Deadline Approaching and Case Now Covers All Publicly Traded Chemours Securities

    SAN FRANCISCO, Dec. 06, 2019 -- Hagens Berman urges The Chemours Company (NYSE: CC) investors who have suffered significant losses on Chemours common stock, options and/or.

  • GlobeNewswire

    DEADLINE ALERT - The Chemours Company (CC) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: December 9, 2019

    Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against The Chemours Company (“Chemours” or the “Company”) (CC) and certain of its officers, on behalf of shareholders who purchased Chemours securities between February 16, 2017 and August 1, 2019 (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws. The Complaint alleges that, throughout the Class Period, Defendants misled investors by representing that Chemours had appropriately accounted and accrued reserves for its environmental liabilities, that the possibility of costs exceeding accrued amounts was "remote," and that, in any event, additional costs would not be material.